North America Single Cell Multiomics Market Outlook, 2030

The single cell multiomics market in North America is undergoing significant growth, fueled by swift developments in molecular biology, next-generation sequencing (NGS), and bioinformatics. Single cell multiomics pertains to the comprehensive analysis of various “omics” layers such as genomics, transcriptomics, epigenomics, and proteomics at the level of individual cells. This technology allows researchers and clinicians to reveal complex cellular mechanisms, variability, and intercellular interactions that bulk cell analysis cannot identify. In North America, the market is advancing due to the region’s strong biomedical research framework, early embrace of precision medicine, and growing investments in biotechnology and life sciences. Agencies such as the National Institutes of Health (NIH), along with private biotech companies, are critical in driving innovation and supporting funding in this area. Key uses of single cell multiomics encompass oncology, immunology, neuroscience, and developmental biology, with cancer research being a primary catalyst. By facilitating in-depth profiling of tumor microenvironments and clonal evolution, multiomics technologies are fast-tracking advancements in personalized oncology and targeted therapy creation. Immunologists utilize single cell platforms to investigate immune reactions at the individual cell level, contributing to the creation of more effective vaccines and immunotherapies. Neuroscientists employ these tools to decode intricate brain networks and neurodegenerative mechanisms. Moreover, the COVID-19 pandemic has heightened the interest in single cell multiomics for analyzing viral pathogenesis, host immune responses, and long-term aftermaths of infection, leading to augmented funding and infrastructure enhancements throughout North America.

The regional market is supported by the presence of major companies like 10x Genomics, BD Biosciences, Illumina, and Thermo Fisher Scientific, which are consistently introducing advanced instruments, reagent kits, and software solutions for multiomic research. Startups and academic research laboratories are equally contributing to innovation, particularly in microfluidics, computational biology, and artificial intelligence-based analysis. Partnerships between academic institutions and industry leaders are promoting the creation of more scalable, cost-effective, and high-throughput multiomic processes. Additionally, North America’s robust intellectual property landscape and regulatory framework encourage market growth and guarantee a flow of translational research moving towards clinical and commercial applications. One of the most promising opportunities for the single cell multiomics market in North America is its incorporation into precision medicine efforts. As healthcare systems transition towards predictive and personalized treatment, single cell technologies are likely to become essential tools for disease identification, prognosis, and therapy selection. This is particularly relevant in oncology, rare genetic conditions, and autoimmune disorders where timely detection and tailored interventions can significantly enhance outcomes. Emerging uses in prenatal diagnostics, regenerative medicine, and pharmacogenomics further illustrate the immense possibilities of multiomic strategies.

The single cell multiomics market in North America is chiefly propelled by the United States, followed by Canada, with both nations playing crucial roles in steering the course of this swiftly advancing sector. The United States leads the regional scene due to its unmatched investment in biomedical research, advanced healthcare systems, and prompt adoption of precision medicine. Esteemed research institutions such as the Broad Institute, Harvard Medical School, Stanford University, and MD Anderson Cancer Center are pioneering efforts to integrate genomics, transcriptomics, and proteomics at the cellular level. Moreover, U. S. -based biotechnology leaders like 10x Genomics, Illumina, Thermo Fisher Scientific, and BD Biosciences are at the cutting edge of creating high-throughput single cell platforms, reagents, and computational resources. Considerable funding from federal entities like the National Institutes of Health (NIH) and the Department of Energy further backs large-scale initiatives that involve single cell multiomic profiling pertaining to cancer, neurobiology, and research on the immune system. Canada, although smaller in market scale, holds an increasingly significant position thanks to its strong focus on life sciences innovation and academic distinction. Institutions such as the University of Toronto, McGill University, and the University of British Columbia are undertaking groundbreaking research in cellular heterogeneity and disease pathways through the use of single cell technologies. The Canadian government and research agencies, including CIHR and Genome Canada, actively finance multiomic projects, frequently in association with U. S. partners, which boosts cross-border collaborations and data exchange. The nation’s vibrant biotechnology industry is also investing in solutions that merge single cell analysis with AI and machine learning for improved data interpretation.

The North America single cell multiomics market, segmented by product type, includes instruments, consumables, and software. Instruments, which encompass advanced sequencers, mass spectrometers, and microfluidic systems, capture a substantial share of the market due to their essential function in data generation. Consumables—comprising reagents, kits, microplates, and chips—represent a continual revenue source and play a key role in sample preparation and processing across multiple omics layers. This segment reaps benefits from strong demand in current research and clinical settings. Software, though smaller in scope, is growing swiftly as the complexity of data requires robust bioinformatics tools for integration, visualization, and interpretation. The rising use of cloud-based solutions and AI-enhanced analytics is fostering innovation in this field. Collectively, these product segments accommodate various workflows in academic, clinical, and industrial environments, ensuring the multiomics pipeline operates efficiently, is scalable, and remains accurate throughout research and translational niches in the North American market. The North American single cell multiomics market is divided by omics type into single cell genomics (SCG), transcriptomics (SCT), proteomics (SCP), and metabolomics (SCM). Single cell genomics leads the market because of its crucial function in pinpointing genetic mutations, copy number variations, and genome-wide associations in individual cells. Close behind is transcriptomics, which provides insights into gene expression and regulation vital for comprehending dynamic cellular activities. Proteomics is experiencing growth with the advent of highly sensitive techniques such as mass cytometry, facilitating protein-level studies at unprecedented detail. Meanwhile, metabolomics—although still developing—presents exciting opportunities for exploring metabolic pathways and cellular physiology in real time. Each omics type contributes distinctly to multi-dimensional profiling, with integrated analysis increasingly vital for thorough biological interpretation. This segmentation showcases the escalating intricacy of single cell research and supports various research objectives, ranging from precision oncology to developmental biology and immunotherapy development within the North American biomedical landscape.

The application spectrum of the North America single cell multiomics market is divided into clinical research, translational research, and synthetic biology. Clinical research leads the way, centered on disease mechanisms and therapeutic advancements. Within this realm, oncology takes precedence by employing single cell methodologies to investigate tumor heterogeneity and microenvironments, trailed by cell therapy, immunology, neurology, and cell biology. These fields benefit significantly from high-resolution observations of cellular behaviors, disease evolution, and therapy responsiveness. Translational research acts as a vital link between laboratory and clinical practices, utilizing multiomics to hasten biomarker identification and drug creation. Synthetic biology, while specialized, is trending upward as researchers craft and manipulate cells using integrated omics data to innovate new biological systems. This broad segmentation highlights the transformative impact of single cell multiomics on medical and biological sciences across various sectors in North America, facilitating the transition of foundational research into applicable clinical knowledge. The North American single-cell multiomics market is categorized by sample type into human, animal, and microbial samples. Human samples lead the market, with subdivisions including cancer tissues, stem cells, immune cells, brain cells, and others. These are essential for comprehending disease mechanisms, cellular interactions, and approaches to personalized medicine. Cancer tissues and immune cells hold particular significance in oncology and immunotherapy research, while stem and brain cells facilitate studies in regenerative medicine and neuroscience. Animal samples act as crucial preclinical models, allowing in vivo confirmation of findings from human cell studies. Microbial samples are increasingly investigated in microbiome and infectious disease research, yielding insights into host-microbe interactions and microbial diversity. This segmentation underscores the versatility and extensive applicability of single-cell multiomics across various fields, enhancing its significance in both fundamental and applied research within North America’s vibrant bioscience landscape.



The North American single-cell multiomics market is divided by workflow into single-cell isolation and dispensing, and single-cell analysis. In isolation and dispensing, methods such as fluorescence-activated cell sorting (FACS), microfluidics, magnetic-activated cell sorting (MACS), random seeding, manual cell picking, and laser capture microdissection permit accurate separation of individual cells from complex biological samples. FACS and microfluidics prevail in this segment due to their scalability and efficiency. During the analysis phase, techniques such as polymerase chain reaction (PCR), next-generation sequencing (NGS), mass cytometry, and mass spectrometry enable in-depth molecular profiling at the single-cell level. These technologies are crucial for obtaining the genomic, transcriptomic, proteomic, and metabolomic profiles required for thorough multiomics integration. This segmentation denotes the essential nature of both isolation and analysis in the single-cell workflow, highlighting the market's focus on precision and technological progress in facilitating next-generation biomedical research throughout North America. End users in the North American single-cell multiomics market encompass research and academic laboratories, biopharmaceutical and biotech firms, contract research organizations (CROs), and additional end users. Research and academic laboratories are the foremost users, promoting innovation through foundational studies in genomics, cancer biology, and neuroscience. These entities benefit from governmental funding and collaborative networks that sustain large-scale, high-throughput initiatives. Biopharma and biotech organizations apply single-cell multiomics for drug discovery, biomarker identification, and the formulation of personalized therapies, especially in oncology and immunology. CROs provide outsourced services such as data generation, bioinformatics, and regulatory assistance, enabling smaller companies and research institutions to utilize advanced technology without significant capital outlay. Other users consist of diagnostic laboratories and hospital-based research centers that are gradually incorporating multiomics into clinical practices. This varied end-user demographic guarantees ongoing demand and the expansion of applications, reinforcing North America’s prominence in converting single-cell multiomics research into tangible healthcare solutions.

Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• North America Single Cell Multiomics Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

Based on Product Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Instruments
• Consumables
• Software

Based on Omics Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Single Cell Genomics (SCG)
• Single Cell Transcriptomics (SCT)
• Single Cell Proteomics (SCP)
• Single Cell Metabolomics (SCM)

By Application, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Clinical Research
• Oncology
• Cell Therapy
• Immunology
• Neurology
• Cell Biology
• Other Types of Clinical Research
• Translation Research
• Synthetic Biology

By Sample Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Human Samples
• Cancer Tissues
• Stem Cells
• Immune Cells
• Brain Cells
• Other Human Samples
• Animal Samples
• Microbial Samples

By Workflow, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Single-Cell Isolation and Dispensing
• Fluorescence-Activated Cell Sorting (FACS)
• Microfluidics
• Magnetic-Activated Cell Sorting (MACS)
• Random Seeding
• Manual Cell Picking
• Laser Capture Microdissection
• Other Technologies of Single-Cell Isolation and Dispensing
• Single-Cell Analysis
• Polymerase Chain Reaction
• Next-Generation Sequencing
• Mass Cytometry
• Mass Spectrometry
• Other Technologies of Single-Cell Analysis

By End User, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Research and Academic Laboratories
• Biopharmaceutical and Biotech Companies
• Contract Research Organizations (CROs)
• Other End Users

The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and listing out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, annual report of companies, analyzing the government generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducted trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers in regional aspects, tier aspects, age group, and gender. Once we have primary data with us we have started verifying the details obtained from secondary sources.

Intended audience
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to agriculture industry, government bodies and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.